Amgen (AMGN),Novartis (NVS) Enter Alzheimer’s Disease, Migraine Research Collaboration

Amgen (NASDAQ: AMGN) announced a neuroscience collaboration with Novartis (NYSE: NVS) in the areas of Alzheimer’s disease and migraine. The collaboration accelerates Amgen’s potential entry into Alzheimer’s disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer’s disease program directed at genetically predisposed individuals at risk of developing Alzheimer’s disease. The collaboration also enables Amgen to focus on the commercialization of its migraine programs in the U.S., Canada and Japan, while leveraging Novartis’ strong commercial capabilities in neuroscience throughout Europe and other markets worldwide. The agreement combines each company’s BACE (beta-site APP-cleaving enzyme-1) programs targeting Alzheimer’s disease into a global co-commercialization and co-development arrangement. Novartis’ Phase 1/2a BACE inhibitor (CNP520) will be the lead molecule and each company’s pre-clinical BACE inhibitor programs will be potential follow-ons. Amgen…


Link to Full Article: Amgen (AMGN),Novartis (NVS) Enter Alzheimer’s Disease, Migraine Research Collaboration